Please login to the form below

Not currently logged in
Email:
Password:

New medical animation company launched

Fusion Medical Animation, a new company specialising in drug mode of action (MOA) animation has been founded by Simon Reid, the former director of production at Random42
Fusion Medical Animation, a new company specialising in drug mode of action (MOA) animation for the pharma, research and healthcare industries has been founded by Simon Reid, the former director of production at Random42. 

MOA animations communicate the biochemical interaction through which a drug substance produces its pharmacological effect. Targeted at physicians, Fusion's animations can lead to greater awareness and adoption of clients' products.

With photo-real animation now common place in film, television and increasingly online, pharma clients are beginning to expect this sort of quality animation and CGI, to explain and market their new drugs and products.

An example of Fusion's MOA animation



Fusion's unique position allows them to combine feature film quality graphics, along with scientifically accurate pharmaceutical MOA expertise.

Before moving to the pharmaceutical industry as director of production at a leading MOA animation agency, Reid spent many years setting up and running various visual effects departments for factual broadcast. 

In addition to their work in the pharmaceutical arena, Fusion has worked on the landmark BBC science series "First Life" presented by Sir David Attenborough as well as producing the medical/science shots for another Attenborough documentary, "Flying Monsters", a stereoscopic production for the new Sky 3D channel and IMAX theatres. 

5th January 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics